In fact, 3 of the 5 tumours (60%) that showed a significant anti-proliferative response uniquely at 0.1 μM Selumetinib (Subset 2) had KRAS or BRAF mutations (Fig. 5g). This evidence concerns the gene BRAF and neoplasm.